Lexaria Bioscience (LEXX) Proxy filing summary

Executive summary

• Annual and Special Meeting scheduled for January 14, 2025, via event conferencing, with proxy materials available online and voting encouraged by proxy or during the meeting.

• Seven director nominees are up for election, including a new CEO, Richard Christopher, following a leadership transition.

• Shareholders will vote on executive compensation, auditor ratification, a significant warrant issuance, and ratification of board actions.

• The board recommends voting in favor of all proposals, including a triennial frequency for say-on-pay votes.

Voting matters and shareholder proposals

• Proposals include election of directors, ratification of MaloneBailey LLP as auditor, advisory approval of executive compensation, advisory vote on frequency of say-on-pay (recommended every three years), approval of warrant issuance, and ratification of board acts.

• Warrant Exercise Proposal seeks approval for issuance of up to 4,608,209 warrants, potentially raising $14 million if fully exercised.

• Failure to approve the warrant proposal would require additional shareholder meetings and could delay research programs.

• No director, executive officer, or major shareholder has a substantial interest in the matters to be acted upon.

Board of directors and corporate governance

• Board consists of seven nominees, with a mix of independent and executive directors; diversity and expertise are emphasized.

• Board committees include Audit and Finance, Compensation, and Governance & Nominating, all with independent members.

• Board leadership transitioned from Christopher Bunka to Richard Christopher as CEO in August 2024.

• Code of Ethics and employee handbook govern conduct, with policies on insider trading and prohibitions on short sales.